This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.

This Mendelian randomization study provided first evidence that the relationship between BP and risk for new-onset AF is likely causal.

Effect of edoxaban versus warfarin on the primary efficacy endpoint and primary safety endpoint was similar in women and men. However, edoxaban reduced risk of several bleeding outcomes to a greater extend in women compared to men.

In a randomized trial of patient with paroxysmal AF, initial strategy of cryoballoon ablation significantly reduced rate of recurrence of atrial tachyarrhythmia compared to antiarrhythmic drug therapy.

This study in a large community-based cohort showed that even low amounts of alcohol consumption are associated with increased risk of incident AF.

Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.

AHA 2020 Use of rivaroxaban was as effective as warfarin in reducing the net clinical outcome of all-cause mortality, major CV events or major bleeding in AF patients with a bioprosthetic mitral valve.

AHA 2020 The VITAL-Rhythm trial showed that daily omega-3 fatty acids and/or vitamin D3 supplementation had no effect on the primary prevention of incident AF.

In the GARFIELD-AF registry, most AF patients received recommended doses of NOAC. Those with nonrecommended doses (underdosing or overdosing) had increased risk of mortality compared to those with recommended doses.

ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.

ESC 2020 The EAST-AFNET4 trial showed that patients with early AF and CV conditions benefit from early rhythm control therapy compared to patients who received standard therapy.

ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.